Pasar al contenido principal

ENSAYO CLINICO SOBRE OPTIMIZACION HEMODINAMICA DE LA PERFUSION CEREBRAL TRAS EL TRATAMIENTO ENDOVASCULAR EN PACIENTES CON ICTUS ISQUEMICO (ESTUDIO HOPE)

ICI20/00137

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación Clínica Independiente
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Centro realización IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Randomized Trial on Hemodynamic Optimization of Cerebral Perfusion after Successful Endovascular Therapy in Patients with Acute Ischemic Stroke (HOPE)

  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Prats Sánchez, Luis Antonio|||0000-0002-3192-4631
  • Ramos-Pachón, Anna|||0000-0002-7136-4245
  • Silva, Y.
  • Giralt Steinhauer, Eva|||0000-0002-7463-0983
  • Flores, A.
  • Ustrell, X.|||0000-0003-3906-8574
  • Moniche, F.
  • Castellanos, M.
  • Aguilera-Simón, Ana|||0000-0003-1428-8212
  • Ezcurra Diaz, Garbiñe|||0000-0002-9511-3117
  • Lambea-Gil, Álvaro|||0000-0003-1785-9201
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Guasch Jiménez, Marina|||0000-0001-6024-8348
  • Martínez-Domeño, Alejandro|||0000-0002-9933-3192
  • Álvarez-Cienfuegos, J.
  • Fortea-Cabo, G.
  • Morales-Caba, L.
  • Rodriguez Campello, Ana Maria|||0000-0001-8621-1420
  • López-Hernández, N.
  • Corona-García, D.J.
  • Freijo-Guerrero, M.M.
  • Luna, A.
  • Tejada-Meza, H.
  • Marta-Moreno, J.
  • Pardo-Galiana, B.
  • Albert-Lacal, L.
  • Sanz-Monllor, A.
  • Marín-Bueno, Rebeca|||0000-0002-0354-6602
Introduction: In patients with acute ischemic stroke (AIS) secondary to intracranial large vessel occlusion, optimal blood pressure (BP) management following endovascular treatment (EVT) has not yet been established. The randomized trial on Hemodynamic Optimization of Cerebral Perfusion after Successful Endovascular Therapy in Patients with Acute Ischemic Stroke (HOPE) (clinicaltrials.gov id: NCT04892511) aims to demonstrate whether hemodynamic optimization using different systolic BP targets following EVT according to the degree of final recanalization, is more effective than currently recommended BP management in improving functional outcomes of patients with AIS. Methods: HOPE is an investigator-initiated multicenter clinical trial with randomized allocation, open-label treatment, and blinded endpoint evaluation (PROBE). Patients with an anterior circulation AIS within 24 h of symptom onset, treated with EVT, and showing successful recanalization (mTICI ?2b) at the end of the procedure, are equally allocated (1:1) to hemodynamic optimization according to the study protocol versus BP management according to current guidelines (?180/105 mm Hg). The protocol includes two different targets of systolic BP depending on the recanalization status (mTICI = 2b: 140 160 mm Hg; mTICI = 2c/ 3: 100 140 mm Hg). The protocol is applied within the first 72 h and includes BP lowering as well as vasopressor therapies when needed. The primary outcome is the proportion of favorable outcome (modified Rankin Scale [mRS] 0 2) at 90 days. Secondary outcomes include the shift on the mRS score, neurological deterioration, symptomatic intracerebral hemorrhage, and mortality. Conclusion: The HOPE trial will provide new information on the safety and efficacy of different BP targets following EVT according to the degree of final recanalization in patients with AIS.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Personalized Blood Pressure Targeting After Endovascular Therapy for Acute Ischemic Stroke

  • Camps-Renom, Pol
  • Guasch-Jiménez, Marina
  • Álvarez-Cienfuegos, Juan
  • López-Hernández, Nicolás
  • Rodríguez-Campello, Ana
  • Tejada-Meza, Herbert
  • et al
Importance Optimal blood pressure (BP) management after successful endovascular therapy for acute ischemic stroke remains uncertain, as intensive lowering has shown no benefit or potential harm in prior trials. Objective To determine whether a reperfusion-guided systolic BP control strategy improves functional outcomes compared with guideline-recommended management after successful endovascular therapy for acute ischemic stroke. Design, Setting, and Participants This investigator-initiated, multicenter, prospective, randomized, open-label clinical trial with blinded end point assessment was conducted among adults with acute ischemic stroke due to anterior circulation large-vessel occlusion who achieved successful reperfusion (modified Thrombolysis in Cerebral Infarction [mTICI] score ≥2b) after endovascular therapy at 11 comprehensive stroke centers in Spain between June 14, 2021, and October 1, 2025, with 90-day follow-up. Data analysis was conducted from February 1 to March 12, 2026. Interventions Participants were randomly assigned (1:1) to a reperfusion-guided systolic BP strategy (140-160 mm Hg for mTICI score of 2b; 100-140 mm Hg for mTICI score of 2c/3) or guideline-recommended management (systolic BP <180 mm Hg) for 72 hours using antihypertensive agents or vasopressors as needed. Main Outcomes and Measures The primary outcome was a favorable functional outcome, defined as a modified Rankin Scale score of 0 to 2 at 90 days, assessed in the intention-to-treat population. Of 446 enrolled patients, 440 were included in the intention-to-treat analysis (mean age, 75 years; 53% women); 6 were excluded due to withdrawal or consent withdrawal. Results Among 440 patients (mean [SD] age, 75 [12] years; 233 [53.0%] women), 215 were assigned to the intervention group and 225 to the control group. At 90 days, 129 patients (60.0%) in the intervention group and 106 (47.1%) in the control group achieved a favorable functional outcome (absolute risk difference, 13.3%; 95% CI, 4.1%-22.6%; P = .005). Hemorrhagic transformation occurred in 48 patients (22.3%) in the intervention group and 71 (31.6%) in the control group (odds ratio, 0.62; 95% CI, 0.41-0.95). The rates of symptomatic intracranial hemorrhage (3.5% vs 3.9%) and 90-day mortality (15.4% vs 15.6%) did not differ between groups. Serious adverse events occurred in 34 patients (15.8%) in the intervention group and 27 (12.0%) in the control group. Conclusions and Relevance In this randomized clinical trial, a reperfusion-guided BP strategy improved functional outcomes and reduced hemorrhagic transformation without increasing major safety events, supporting a tailored approach to postthrombectomy BP management.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

A Randomized Trial on Hemodynamic Optimization of Cerebral Perfusion after Successful Endovascular Therapy in Patients with Acute Ischemic Stroke (HOPE)

  • Camps-Renom, Pol
  • Guasch-Jiménez, Marina
  • Martínez-Domeño, Alejandro
  • Prats-Sánchez, Luis
  • Ramos-Pachón, Anna
  • Álvarez-Cienfuegos, Juan
  • Silva, Yolanda
  • Fortea-Cabo, Gerardo
  • Morales-Caba, Luis
  • Rodríguez-Campello, Ana
  • Giralt-Steinhauer, Eva
  • Flores, Alan
  • Ustrell, Xavier
  • López-Hernández, Nicolás
  • Corona-García, Diego José
  • Freijo-Guerrero, Mari Mar
  • Luna, Alain
  • Tejada-Meza, Herbert
  • Marta-Moreno, Javier
  • Moniche, Francisco
  • Pardo-Galiana, Blanca
  • Castellanos, Mar
  • Albert-Lacal, Laura
  • Sanz-Monllor, Ainara
  • Aguilera-Simón, Ana
  • Marín, Rebeca
  • Ezcurra-Díaz, Garbiñe
  • Lambea-Gil, Álvaro
  • Martí-Fàbregas, Joan
Introduction: In patients with acute ischemic stroke (AIS) secondary to intracranial large vessel occlusion, optimal blood pressure (BP) management following endovascular treatment (EVT) has not yet been established. The randomized trial on Hemodynamic Optimization of Cerebral Perfusion after Successful Endovascular Therapy in Patients with Acute Ischemic Stroke (HOPE) (clinicaltrials.gov id: NCT04892511) aims to demonstrate whether hemodynamic optimization using different systolic BP targets following EVT according to the degree of final recanalization, is more effective than currently recommended BP management in improving functional outcomes of patients with AIS. Methods: HOPE is an investigator-initiated multicenter clinical trial with randomized allocation, open-label treatment, and blinded endpoint evaluation (PROBE). Patients with an anterior circulation AIS within 24 h of symptom onset, treated with EVT, and showing successful recanalization (mTICI ≥2b) at the end of the procedure, are equally allocated (1:1) to hemodynamic optimization according to the study protocol versus BP management according to current guidelines (≤180/105 mm Hg). The protocol includes two different targets of systolic BP depending on the recanalization status (mTICI = 2b: 140–160 mm Hg; mTICI = 2c/3: 100–140 mm Hg). The protocol is applied within the first 72 h and includes BP lowering as well as vasopressor therapies when needed. The primary outcome is the proportion of favorable outcome (modified Rankin Scale [mRS] 0–2) at 90 days. Secondary outcomes include the shift on the mRS score, neurological deterioration, symptomatic intracerebral hemorrhage, and mortality. Conclusion: The HOPE trial will provide new information on the safety and efficacy of different BP targets following EVT according to the degree of final recanalization in patients with AIS.